0       0

AMDA's 32nd Annual Symposium


C15 - Avoiding and Eliminating Inappropriate Antipsychotic Use in Nursing Home Residents with Dementia: Characteristics, Outcomes and Alternative Approaches


Mar 7, 2009 2:30pm ‐ Mar 7, 2009 3:30pm

Standard: $24.00

Description

AMDCP Credit Designation:

This session has been approved for a total of 1 Management credit hours toward certification as a Certified Medical Director in Long Term Care (CMD).

The American Medical Directors Association designates this educational activity fora maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Presenter(s): Jeffrey Nichols, MD; Louis Mudannayake, MD; Christie Teigland, PhD

Disclosure(s):
Jeffrey Nichols, MD, CMD has no relevant financial relationships to disclose. Dr.Nichols will discuss off-label use of Atypical Antipsychotics for treatment of behavioral disorders in Dementia. Their use will be discouraged, but their common use will be reviewed.
Louis Mudannayake, MD has no relevant financial relationships to disclose.
Christie Teigland, PhD has no relevant financial relationships to disclose. Dr. Teigland will discuss research related to off-label use of antipsychotic medications in the elderly, but no specific drug or drug research will be discussed,

Session Description:
This session will discuss anti-psychotic utilization trends and treatment patterns in nursing facility residents with dementia in the context of the FDA black box warning, tougher CMS regulations, and new guidelines based on recent evidence regarding safety and efficacy of the medications; contrast characteristics of residents treated vs. not treated with antipsychotics and weighing polypharmacy impacts; and evaluating approaches for avoiding and reducing unnecessary and off-label use of antipsychotic medications while effectively managing negative/disruptive behaviors in dementia residents.

Learning Objectives:
  • Discuss antipsychotic utilization trends and treatment patterns in nursing facility residents with dementia in the context of the FDA blackbox warning, tougher CMS regulations, and new guidelines
  • Identify resident characteristics and outcomes associated withtreatment with antipsychotic medications and weigh polypharmacy impacts
  • Evaluate approaches for avoiding and reducing unnecessary andoff-label use of antipsychotic medications while effectively managingnegative/disruptive behaviors in dementia residents

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content